
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of June, 2020

Commission File Number: 001-38452

MEREO BIOPHARMA GROUP PLC

(Translation of registrant's name into English)

**4th Floor, One Cavendish Place,
London, W1G 0QE, United Kingdom**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Exhibit Index**Exhibit
No.****Exhibit**

99.1 Press release dated June 9, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: June 9, 2020

MEREO BIOPHARMA GROUP PLC

By: /s/ Charles Sermon

Name: Charles Sermon

Title: General Counsel

Publication of Circular and Notice of General Meeting

London and Redwood City, Calif., June 9, 2020 – Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) announces that, further to the announcement regarding the completed Private Placement of \$70 million (£56 million) (the “Fundraising”) made on June 4, 2020, it has today published a circular (the “Circular”) in connection with the Fundraising.

The Circular contains a notice convening a General Meeting of the Company, at which certain resolutions in connection with the Fundraising will be put to shareholders. The meeting will be held at the 4th Floor, One Cavendish Place, London W1G 0QF, United Kingdom on 30 June 2020 at 11.00 a.m. (London time). In accordance with the UK Government’s COVID-19 measures, ordinary shareholders are not expected to be allowed to attend the General Meeting in person, shareholders are therefore encouraged to submit their proxy vote electronically.

The Circular and the Notice of General Meeting will also be available for viewing on Mereo’s website at <https://www.mereobiopharma.com/ngm> .

Terms used in this announcement shall have the same meaning as those used in the Circular.

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with oncology and rare diseases. Mereo’s strategy is to selectively acquire product candidates for oncology and rare diseases that have already received significant investment from pharmaceutical and large biotechnology companies and that have substantial preclinical, clinical and manufacturing data packages. Mereo’s lead oncology product candidate, etigilimab, an anti-TIGIT, has completed a Phase 1a and Phase 1b for a range of solid tumor types and the second product candidate, navicixizumab, for ovarian cancer has been licensed to Oncologie Inc. for up to \$300M in milestone payments. Mereo’s lead rare disease product candidate, setrusumab, has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta (“OI”) and a pivotal Phase 3 study design in paediatrics has been agreed with the FDA and EMA. Mereo’s second lead product candidate, alvelestat, is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency (“AATD”). Mereo plans to form a strategic partnership for setrusumab prior to initiation of the paediatric pivotal study. Following successful completion of Phase 2, Mereo is seeking partnerships for its two additional clinical-stage product candidates; acumapimod for the treatment of acute exacerbations of chronic obstructive pulmonary disease (“AECOPD”), leflutrolole for the treatment of infertility and hypogonadotropic hypogonadism (“HH”) in obese men.

Additional Information

The person responsible for arranging the release of this information on behalf of the Company is Charles Sermon, General Counsel.

Mereo BioPharma Contacts:

Mereo Denise Scots-Knight, Chief Executive Officer	+44 (0)333 023 7300
Cantor Fitzgerald Europe (Nominated Adviser and Broker to Mereo) Phil Davies Will Goode	+44 (0)20 7894 7000
Burns McClellan (US Public Relations Adviser to Mereo) Lisa Burns Steve Klass	+01 (0) 212 213 0006
FTI Consulting (UK Public Relations Adviser to Mereo) Simon Conway Ciara Martin	+44 (0)20 3727 1000
Investors	<u>investors@mereobiopharma.com</u>